Welcome to the UPF Digital Repository

Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.

Show simple item record

dc.contributor.author García-Sanz, Ramón
dc.contributor.author Albert, Oriol
dc.contributor.author Moreno, María J.
dc.contributor.author Rubia, Javier de la
dc.contributor.author Payer, Angel R.
dc.contributor.author Hernández, Miguel T.
dc.contributor.author Palomera, Luis
dc.contributor.author Teruel, Ana I.
dc.contributor.author Blanchard, María J.
dc.contributor.author Gironella, Mercedes
dc.contributor.author Ribas, Paz
dc.contributor.author Bargay, Joan
dc.contributor.author Abella Monreal, Eugenia
dc.contributor.author Granell, Miquel
dc.contributor.author Ocio, Enrique M.
dc.contributor.author Ribera, Josep Maria
dc.contributor.author San Miguel, Jesús F.
dc.contributor.author Mateos, María V.
dc.contributor.author Spanish Myeloma Group (GEM/PETHEMA).
dc.date.accessioned 2015-11-24T12:40:09Z
dc.date.available 2015-11-24T12:40:09Z
dc.date.issued 2015
dc.identifier.citation García-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer AR, Hernández MT, Palomera L, Teruel AI, Blanchard MJ, Gironella M, Ribas P, Bargay J, Abellá E, Granell M, Ocio EM, Ribera JM, San Miguel JF, Mateos MV. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. Haematologica. 2015;100(9)
dc.identifier.issn 0390-6078
dc.identifier.uri http://hdl.handle.net/10230/25195
dc.description.abstract This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid (4 mg iv/4 weeks, 12 doses) (n=51) or not (n=49). Experimental and control groups were well balanced for disease and prognostic features. Zoledronic acid did not show an antitumor effect according to changes in M-component. However, there were fewer symptomatic progressions in the experimental group than in the control group (34 versus 41, respectively; P=0.05) resulting in a median time to symptoms of 16 versus 10 months (P=0.161). The median time to next therapy was also slightly longer for the treated group than the untreated, control group (13.4 versus 10.1 months), although the difference was not statistically significant (P=0.360). The pattern of relapses was different for treated versus control patients: progressive bone disease (8 versus 20), anemia (24 versus 18), renal dysfunction (1 versus 2), and plasmacytomas (1 versus 1, respectively). This concurred with fewer skeletal-related events in the treated group than in the control group (2 versus 14), with a projected 4-year event proportion of 6% versus 40% (P<0.001). In summary, zoledronic acid monotherapy does not show an antitumor effect on biochemical relapses in multiple myeloma, but does reduce the risk of progression with symptomatic bone disease and skeletal complications. This trial was registered in the ClinicalTrials.gov database with code NCT01087008.
dc.description.sponsorship This work was supported by an unrestricted grant from Novartis Farmaceutica S.A., Barcelona, Spain and sponsored by GEM/PETHEMA. Part of the work was also done thanks to grants PS09/01450 and PI12/02311 from the Spanish “Instituto de Salud Carlos III (ISCIII)” and Fondo Europeo de Desarrollo Regional (FEDER), the Spanish Ministry of Economy and Competitiveness and the European Regional Development Fund (ERDF) “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010), the grant RD12/0036/0069 from “Red Temática de Investigación Cooperativa en Cáncer (RTICC), and grant GCB-120981SAN from the “Asociación Española Contra el Cáncer (AECC)”.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Ferrata Storti Foundation
dc.relation.ispartof Haematologica. 2015;100(9)
dc.rights ©2015 Ferrata Storti Foundation. This is an open-access paper. http://dx.doi.org/10.3324/haematol.2015.128439
dc.subject.other Mieloma múltiple
dc.title Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3324/haematol.2015.128439
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking